The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWERLung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in NeverSmoker Predominant Actionable Driver Mutation Positive NSCLC? User montaukwhaler, in the non small cell lung cancer subreddit, 27 Jun 2023